valproic acid has been researched along with Obesity in 71 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 9.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 8.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "Objectives: Clozapine-induced myocarditis may be a hypersensitivity reaction due to titration that was too rapid for a patient's clozapine metabolism." | 8.12 | Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. ( Coleman, JK; Cotes, RO; De Leon, J; Goldsmith, DR; Koenig, M; McCollum, B; Shelton, C; Spivey, JK, 2022) |
| "To investigate the presence of insulin resistance in obese children with idiopathic epilepsy on valproic acid (VPA) monotherapy in comparison to obese otherwise healthy subjects." | 7.81 | Insulin resistance in patients on valproic acid: relation to adiponectin. ( Aly, RH; Amr, NH; Megahed, AA; Saad, WE, 2015) |
| "Valproic acid (VPA) is a useful antiepileptic drug for controlling different types of epilepsy." | 7.81 | [The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid]. ( Carmona-Vazquez, CR; Diaz-Garcia, L; Greenawalt, SR; Pena-Landin, DM; Ruiz-Garcia, M, 2015) |
| "Weight gain is a well-known unwanted effect of valproic acid (VPA) therapy." | 7.77 | Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. ( Balestri, P; Barlocco, EG; Casarosa, E; Grosso, S; Luisi, S; Matera, M; Mostardini, R; Petraglia, F, 2011) |
| " However, the results of the present study do not suggest an independent role for leptin in the pathogenesis of VPA-related obesity." | 7.71 | Serum insulin and leptin levels in valproate-associated obesity. ( Isojärvi, JI; Knip, M; Kotila, M; Pakarinen, A; Pylvänen, V; Turkka, J, 2002) |
| "In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women." | 7.71 | Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. ( Abraham, I; Alge, A; Bauer, G; Haslinger, M; Lechleitner, M; Luef, G; Seppi, K; Trinka, E; Unterberger, I; Windisch, J, 2002) |
| "The interaction between clearance of phenytoin, valproic acid, phenobarbital and carbamazepine, and changes in body weight was determined in a 19-year-old obese woman with epilepsy (body weight 93 kg, BMI 36." | 7.69 | Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study. ( Ashikari, Y; Chiba, S; Kodama, Y; Kuranari, M; Sakata, T; Takeyama, M, 1996) |
| "Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| "TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase." | 5.16 | Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. ( Axelson, DA; Birmaher, B; Emslie, G; Joshi, P; Luby, J; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Yenokyan, G, 2012) |
| "Body mass index (BMI) and fasting serum concentrations of insulin and lipids were measured in 102 men with epilepsy who were treated with VPA, carbamazepine (CBZ), or oxcarbazepine (OXC) monotherapy." | 5.10 | Fasting serum insulin and lipid levels in men with epilepsy. ( Isojärvi, JI; Knip, M; Kotila, M; Myllylä, VV; Pakarinen, AJ; Pylvänen, V; Rättyä, J; Turkka, J, 2003) |
| "Twenty-two female outpatients with a DSM-IV diagnosis of bipolar disorder who were between the ages of 18 and 45 years (inclusive) and who were taking lithium and/or divalproex (10, divalproex monotherapy; 10, lithium monotherapy; 2, divalproex/lithium combination therapy) were evaluated." | 5.09 | Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. ( Altshuler, LL; Burt, VK; Gudeman, D; Hendrick, V; Korenman, S; Rasgon, NL; Tanavoli, S, 2000) |
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 5.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 4.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "Valproic acid (VPA), a widely used antiepileptic drug, has broad-spectrum activity against both generalized and partial epilepsy." | 4.85 | Valproate-induced insulin resistance and obesity in children. ( Chiarelli, F; la Torre, R; Mohn, A; Trotta, D; Verrotti, A, 2009) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| "Mice in the HFD group displayed more severe albuminuria, glomerular hypertrophy, renal oxidative damage, inflammation, and lipid accumulation than mice with the normal diet (ND) group, as well as lower levels of intestinal SCFA valproic acid, colonic inflammation, and tight junction protein downregulation." | 4.31 | ACT001 Alleviates chronic kidney injury induced by a high-fat diet in mice through the GPR43/AMPK pathway. ( Chen, Z; Li, P; Li, Y; Liu, J; Mi, Y; Niu, B; Zhou, H; Zhou, Y, 2023) |
| "Objectives: Clozapine-induced myocarditis may be a hypersensitivity reaction due to titration that was too rapid for a patient's clozapine metabolism." | 4.12 | Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. ( Coleman, JK; Cotes, RO; De Leon, J; Goldsmith, DR; Koenig, M; McCollum, B; Shelton, C; Spivey, JK, 2022) |
| "To investigate the presence of insulin resistance in obese children with idiopathic epilepsy on valproic acid (VPA) monotherapy in comparison to obese otherwise healthy subjects." | 3.81 | Insulin resistance in patients on valproic acid: relation to adiponectin. ( Aly, RH; Amr, NH; Megahed, AA; Saad, WE, 2015) |
| "Valproic acid (VPA) is a useful antiepileptic drug for controlling different types of epilepsy." | 3.81 | [The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid]. ( Carmona-Vazquez, CR; Diaz-Garcia, L; Greenawalt, SR; Pena-Landin, DM; Ruiz-Garcia, M, 2015) |
| "Weight gain is a well-known unwanted effect of valproic acid (VPA) therapy." | 3.77 | Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. ( Balestri, P; Barlocco, EG; Casarosa, E; Grosso, S; Luisi, S; Matera, M; Mostardini, R; Petraglia, F, 2011) |
| "Our study was carried out to ascertain the role of valproic acid for inducing metabolic disorders like hyperinsulinemia, insulin resistance and metabolic syndrome." | 3.77 | Fasting insulin and HOMA-index changes in patients treated with valproic acid. ( Javashvili, L; Kasradze, S; Mania, M; Okujava, N, 2011) |
| "This study was undertaken in 2 parts to investigate the relationship between body size and insulin resistance during treatment with valproic acid in children." | 3.76 | Weight gain and insulin resistance in children treated with valproate: the influence of time. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Masuccio, F; Mohn, A; Verrotti, A, 2010) |
| "Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight." | 3.75 | Nonalcoholic fatty liver disease during valproate therapy. ( Chiarelli, F; Di Marco, G; la Torre, R; Pelliccia, P; Verrotti, A, 2009) |
| " Anthropometric measurements, staging of pubertal maturation, and clinical manifestations of hyperandrogenism were assessed, as well as measurement of serum levels of testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and free androgen index (FAI)." | 3.72 | Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. ( Abd El-Basset, FZ; El Barbary, NS; El-Khayat, HA; Hakky, SM; Mohamed, MS; Nassef, NM; Tohamy, SM; Tomoum, HY; Zaky, AA, 2004) |
| "In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women." | 3.71 | Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. ( Abraham, I; Alge, A; Bauer, G; Haslinger, M; Lechleitner, M; Luef, G; Seppi, K; Trinka, E; Unterberger, I; Windisch, J, 2002) |
| " However, the results of the present study do not suggest an independent role for leptin in the pathogenesis of VPA-related obesity." | 3.71 | Serum insulin and leptin levels in valproate-associated obesity. ( Isojärvi, JI; Knip, M; Kotila, M; Pakarinen, A; Pylvänen, V; Turkka, J, 2002) |
| "The interaction between clearance of phenytoin, valproic acid, phenobarbital and carbamazepine, and changes in body weight was determined in a 19-year-old obese woman with epilepsy (body weight 93 kg, BMI 36." | 3.69 | Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study. ( Ashikari, Y; Chiba, S; Kodama, Y; Kuranari, M; Sakata, T; Takeyama, M, 1996) |
| "Valproic acid (VPA) is a widely prescribed anticonvulsant for the treatment of epilepsy." | 1.40 | Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice. ( Avery, LB; Bumpus, NN, 2014) |
| "Valproic acid was found to have a significant impact on the worsening of BMI from overweight to obesity (P<0." | 1.40 | The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia. ( Ching, HY; Wang, PS; Wu, SL, 2014) |
| " No correlation was found between duration or dosage of treatment and BMI-SDS, height-SDS, or androgen level." | 1.34 | Endocrine effects of valproate in adolescent girls with epilepsy. ( de Vries, L; Goldberg-Stern, H; Karasik, A; Kiviti, S; Landau, Z; Phillip, M, 2007) |
| "Metabolic syndrome was more frequently associated with VPA-treated patients (41." | 1.34 | Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. ( Kim, JY; Lee, HW, 2007) |
| "Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity." | 1.33 | Drug-induced weight gain. ( Apovian, CM; Ness-Abramof, R, 2005) |
| "Polycystic ovary syndrome was more common in patients on medication (38%; in 63% on VPA, in 25% on other medication) than in patients off medication (6%) or in controls (11%) (p = 0." | 1.32 | Long-term reproductive endocrine health in young women with epilepsy during puberty. ( Isojärvi, JI; Järvelä, IY; Knip, M; Mikkonen, K; Pakarinen, AJ; Tapanainen, JS; Vainionpää, LK, 2004) |
| " The patients were divided into two groups based on the initial dosing regimen." | 1.31 | Tolerability of oral loading of divalproex sodium in child psychiatry inpatients. ( Feaster, CS; Good, CR; Krecko, VF, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.41) | 18.7374 |
| 1990's | 5 (7.04) | 18.2507 |
| 2000's | 35 (49.30) | 29.6817 |
| 2010's | 26 (36.62) | 24.3611 |
| 2020's | 4 (5.63) | 2.80 |
| Authors | Studies |
|---|---|
| Marjani, M | 1 |
| Dolab, N | 1 |
| Kamkar, MZ | 1 |
| Amiriani, T | 1 |
| Yuzugulen, J | 1 |
| Marjani, A | 1 |
| Koenig, M | 1 |
| McCollum, B | 1 |
| Spivey, JK | 1 |
| Coleman, JK | 1 |
| Shelton, C | 1 |
| Cotes, RO | 1 |
| Goldsmith, DR | 1 |
| De Leon, J | 1 |
| Zhou, Y | 1 |
| Chen, Z | 1 |
| Zhou, H | 1 |
| Niu, B | 1 |
| Liu, J | 1 |
| Li, Y | 2 |
| Mi, Y | 1 |
| Li, P | 1 |
| Platzer, M | 1 |
| Fellendorf, FT | 1 |
| Bengesser, SA | 1 |
| Birner, A | 1 |
| Dalkner, N | 1 |
| Hamm, C | 1 |
| Lenger, M | 1 |
| Maget, A | 1 |
| Pilz, R | 1 |
| Queissner, R | 1 |
| Reininghaus, B | 1 |
| Reiter, A | 1 |
| Mangge, H | 1 |
| Zelzer, S | 1 |
| Kapfhammer, HP | 1 |
| Reininghaus, EZ | 1 |
| Gotlib, D | 1 |
| Ramaswamy, R | 1 |
| Kurlander, JE | 1 |
| DeRiggi, A | 1 |
| Riba, M | 1 |
| Bai, X | 1 |
| Xu, C | 1 |
| Wen, D | 1 |
| Chen, Y | 1 |
| Li, H | 1 |
| Wang, X | 1 |
| Zhou, L | 1 |
| Huang, M | 1 |
| Jin, J | 1 |
| Kmietowicz, Z | 1 |
| Avery, LB | 1 |
| Bumpus, NN | 1 |
| Chukwu, J | 1 |
| Delanty, N | 1 |
| Webb, D | 1 |
| Cavalleri, GL | 1 |
| Wang, PS | 1 |
| Wu, SL | 1 |
| Ching, HY | 1 |
| Aly, RH | 1 |
| Amr, NH | 1 |
| Saad, WE | 1 |
| Megahed, AA | 1 |
| Barnhorst, A | 1 |
| Xiong, GL | 1 |
| Carmona-Vazquez, CR | 1 |
| Ruiz-Garcia, M | 1 |
| Pena-Landin, DM | 1 |
| Diaz-Garcia, L | 1 |
| Greenawalt, SR | 1 |
| Ma, L | 1 |
| Tang, H | 1 |
| Yin, Y | 1 |
| Yu, R | 1 |
| Zhao, J | 1 |
| Mulholland, MW | 1 |
| Zhang, W | 1 |
| Nuttall, JR | 1 |
| Chen, PS | 3 |
| Chang, HH | 3 |
| Huang, CC | 1 |
| Lee, CC | 1 |
| Lee, SY | 1 |
| Chen, SL | 1 |
| Huang, SY | 1 |
| Yang, YK | 3 |
| Lu, RB | 3 |
| Aydin, S | 1 |
| Dag, E | 1 |
| Elmslie, JL | 1 |
| Porter, RJ | 1 |
| Joyce, PR | 1 |
| Hunt, PJ | 1 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| Verrotti, A | 9 |
| Di Marco, G | 1 |
| la Torre, R | 2 |
| Pelliccia, P | 1 |
| Chiarelli, F | 9 |
| Trotta, D | 2 |
| Mohn, A | 3 |
| Chou, CH | 1 |
| Gean, PW | 2 |
| Huang, HC | 2 |
| Lin, CY | 1 |
| Kenna, HA | 1 |
| Jiang, B | 1 |
| Rasgon, NL | 2 |
| Manco, R | 2 |
| Agostinelli, S | 1 |
| Coppola, G | 2 |
| Bond, DJ | 1 |
| Kauer-Sant'Anna, M | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| Abaci, A | 1 |
| Saygi, M | 1 |
| Yis, U | 1 |
| Demir, K | 1 |
| Dirik, E | 1 |
| Bober, E | 1 |
| Masuccio, F | 1 |
| Chiavaroli, V | 1 |
| de Giorgis, T | 1 |
| Giannini, C | 1 |
| D'Egidio, C | 1 |
| Grosso, S | 1 |
| Luisi, S | 1 |
| Mostardini, R | 1 |
| Matera, M | 1 |
| Barlocco, EG | 1 |
| Casarosa, E | 1 |
| Balestri, P | 1 |
| Petraglia, F | 1 |
| Mania, M | 1 |
| Javashvili, L | 1 |
| Kasradze, S | 1 |
| Okujava, N | 1 |
| Kanemura, H | 1 |
| Sano, F | 1 |
| Maeda, Y | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
| Fang, J | 1 |
| Chen, S | 1 |
| Tong, N | 1 |
| Chen, L | 1 |
| An, D | 1 |
| Mu, J | 1 |
| Zhou, D | 1 |
| Vitiello, B | 1 |
| Riddle, MA | 1 |
| Yenokyan, G | 1 |
| Axelson, DA | 1 |
| Wagner, KD | 1 |
| Joshi, P | 1 |
| Walkup, JT | 1 |
| Luby, J | 1 |
| Birmaher, B | 1 |
| Ryan, ND | 1 |
| Emslie, G | 1 |
| Robb, A | 1 |
| Tillman, R | 1 |
| Youngson, NA | 1 |
| Morris, MJ | 1 |
| Kemp, DE | 1 |
| De Hert, M | 1 |
| Rahman, Z | 1 |
| Fyans, P | 1 |
| Eudicone, JM | 1 |
| Marler, SV | 1 |
| Baker, RA | 1 |
| Carlson, BX | 1 |
| Swartz, HA | 1 |
| Fagiolini, A | 1 |
| Krępuła, K | 1 |
| Bidzińska-Speichert, B | 1 |
| Lenarcik, A | 1 |
| Tworowska-Bardzińska, U | 1 |
| Luef, G | 1 |
| Abraham, I | 1 |
| Haslinger, M | 1 |
| Trinka, E | 1 |
| Seppi, K | 1 |
| Unterberger, I | 1 |
| Alge, A | 1 |
| Windisch, J | 1 |
| Lechleitner, M | 1 |
| Bauer, G | 1 |
| Saito, E | 1 |
| Kafantaris, V | 1 |
| Akdeniz, F | 1 |
| Taneli, F | 1 |
| Noyan, A | 1 |
| Yüncü, Z | 1 |
| Vahip, S | 1 |
| Pylvänen, V | 3 |
| Knip, M | 6 |
| Pakarinen, AJ | 4 |
| Turkka, J | 2 |
| Kotila, M | 2 |
| Rättyä, J | 2 |
| Myllylä, VV | 2 |
| Isojärvi, JI | 5 |
| Biton, V | 1 |
| Levisohn, P | 1 |
| Hoyler, S | 1 |
| Vuong, A | 1 |
| Hammer, AE | 1 |
| Wirrell, EC | 1 |
| Bosnak, M | 1 |
| Dikici, B | 1 |
| Haspolat, K | 1 |
| Dagli, A | 1 |
| Dikici, S | 1 |
| Tavakoli, SA | 1 |
| Arguisola, MS | 1 |
| di Corcia, G | 1 |
| Salladini, C | 1 |
| Morgese, G | 1 |
| Mikkonen, K | 1 |
| Vainionpää, LK | 1 |
| Järvelä, IY | 1 |
| Tapanainen, JS | 2 |
| Greco, R | 2 |
| Latini, G | 2 |
| De Simone, M | 1 |
| El-Khayat, HA | 1 |
| Abd El-Basset, FZ | 1 |
| Tomoum, HY | 1 |
| Tohamy, SM | 1 |
| Zaky, AA | 1 |
| Mohamed, MS | 1 |
| Hakky, SM | 1 |
| El Barbary, NS | 1 |
| Nassef, NM | 1 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Klein, KM | 1 |
| Hamer, HM | 1 |
| Reis, J | 1 |
| Schmidtke, J | 1 |
| Oertel, WH | 1 |
| Theisen, FM | 1 |
| Hebebrand, J | 1 |
| Rosenow, F | 1 |
| Ness-Abramof, R | 1 |
| Apovian, CM | 1 |
| Iannetti, P | 1 |
| Pakarinen, A | 2 |
| Isojärvi, J | 1 |
| de Vries, L | 1 |
| Karasik, A | 1 |
| Landau, Z | 1 |
| Phillip, M | 1 |
| Kiviti, S | 1 |
| Goldberg-Stern, H | 1 |
| Kim, B | 1 |
| Kim, SJ | 1 |
| Son, JI | 1 |
| Joo, YH | 1 |
| Kim, JY | 1 |
| Lee, HW | 1 |
| Scardapane, A | 1 |
| Franzoni, E | 1 |
| Vorum, H | 2 |
| Gram, L | 1 |
| Honoré, B | 1 |
| Laatikainen, TJ | 1 |
| Juntunen, KT | 1 |
| Kuranari, M | 1 |
| Chiba, S | 1 |
| Ashikari, Y | 1 |
| Kodama, Y | 1 |
| Sakata, T | 1 |
| Takeyama, M | 1 |
| Johnston, HF | 1 |
| Altshuler, LL | 1 |
| Gudeman, D | 1 |
| Burt, VK | 1 |
| Tanavoli, S | 1 |
| Hendrick, V | 1 |
| Korenman, S | 1 |
| Henderson, DC | 1 |
| Cagliero, E | 1 |
| Gray, C | 1 |
| Nasrallah, RA | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Goff, DC | 1 |
| Good, CR | 1 |
| Feaster, CS | 1 |
| Krecko, VF | 1 |
| Stephen, LJ | 1 |
| Kwan, P | 1 |
| Shapiro, D | 1 |
| Dominiczak, M | 1 |
| Brodie, MJ | 1 |
| Taubøll, E | 1 |
| van Parys, J | 1 |
| Harbo, HF | 1 |
| Dale, PO | 1 |
| Fauser, BC | 1 |
| Gjerstad, L | 1 |
| Koivunen, R | 1 |
| Brodersen, R | 1 |
| Jørgensen, N | 1 |
| Krukow, N | 1 |
| Squadrito, F | 1 |
| Sturniolo, R | 1 |
| Arcadi, F | 1 |
| Arcoraci, V | 1 |
| Caputi, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Early Age Mania (TEAM) Study[NCT00057681] | Phase 3 | 379 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 2.49 |
| Randomized Medication - Divalproex Sodium | 2.73 |
| Randomized Medication - Risperidone | 1.70 |
The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 24.06 |
| Randomized Medication - Divalproex Sodium | 26.31 |
| Randomized Medication - Risperidone | 14.58 |
The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | side effects at week 8 (Mean) |
|---|---|
| Randomized Medication - Lithium | 5.11 |
| Randomized Medication - Divalproex Sodium | 4.95 |
| Randomized Medication - Risperidone | 3.70 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
10 reviews available for valproic acid and Obesity
| Article | Year |
|---|---|
Valproic Acid in Women and Girls of Childbearing Age.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Antimanic Agents; Europe; Female; H | 2017 |
Weight change, genetics and antiepileptic drugs.
Topics: Animals; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Huma | 2014 |
The plausibility of maternal toxicant exposure and nutritional status as contributing factors to the risk of autism spectrum disorders.
Topics: Animals; Autism Spectrum Disorder; Benzhydryl Compounds; Brain; Diethylhexyl Phthalate; Disease Mode | 2017 |
Valproate-induced insulin resistance and obesity in children.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Insulin Resistance; Obesity; Valproic Acid; Weight Gain | 2009 |
Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment.
Topics: Bipolar Disorder; Dyslipidemias; Endocrine System Diseases; Female; Humans; Hypogonadism; Hypothalam | 2009 |
Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
Topics: Androgens; Anticonvulsants; Epilepsy; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; | 2011 |
What obesity research tells us about epigenetic mechanisms.
Topics: Adipogenesis; Animals; Diet, High-Fat; DNA Methylation; Environmental Exposure; Epigenesis, Genetic; | 2013 |
Cardiovascular disease and bipolar disorder: risk and clinical implications.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Cardiovascular Diseases; | 2012 |
Psychiatric disorders related to polycystic ovary syndrome.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Feeding and Eating Disorders; Female; Hirsutism; Hor | 2012 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
8 trials available for valproic acid and Obesity
| Article | Year |
|---|---|
Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy.
Topics: Adolescent; Anticonvulsants; Behavior Therapy; Body Mass Index; Child; Epilepsy; Female; Humans; Hyp | 2012 |
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study.
Topics: Adolescent; Age Factors; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit | 2012 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
Fasting serum insulin and lipid levels in men with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Epilepsy; Fasting; Humans; Hyper | 2003 |
Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Body Mass Index; Child; Double-Blind Metho | 2003 |
Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate.
Topics: Adolescent; alpha-Tocopherol; Anticonvulsants; Antioxidants; beta Carotene; Body Weight; Carotenoids | 2004 |
Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Co | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
53 other studies available for valproic acid and Obesity
| Article | Year |
|---|---|
Gender and Body Mass Index-Related Serum Level of Adipokines and Metabolic Syndrome Components in Bipolar Patients Who Received Lithium and Valproic Acid.
Topics: Adipokines; Adiponectin; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Female; Humans; Leptin | 2022 |
Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases.
Topics: Antipsychotic Agents; Clozapine; Hospitals; Humans; Male; Myocarditis; Obesity; Schizophrenia; Valpr | 2022 |
ACT001 Alleviates chronic kidney injury induced by a high-fat diet in mice through the GPR43/AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Female; Inflammation; Kelch-Like ECH-Associa | 2023 |
The Relationship Between Food Craving, Appetite-Related Hormones and Clinical Parameters in Bipolar Disorder.
Topics: Acylation; Adult; Anthropometry; Appetite; Bipolar Disorder; Craving; Cross-Sectional Studies; Fast | 2020 |
Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Asian People; Body Mass Index; Body Weight; CD36 Antige | 2018 |
More drug studies need to include pregnant women, says bulletin.
Topics: Anticonvulsants; Clinical Trials as Topic; Drug Industry; Female; Humans; Hypnotics and Sedatives; M | 2013 |
Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice.
Topics: Acetyl-CoA Carboxylase; Adiposity; Adult; AMP-Activated Protein Kinases; Animals; Blood Glucose; Cel | 2014 |
The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Diagnostic and Statistical Manua | 2014 |
Insulin resistance in patients on valproic acid: relation to adiponectin.
Topics: Adiponectin; Adolescent; Anticonvulsants; Blood Glucose; Child; Epilepsy, Generalized; Female; Human | 2015 |
Pulmonary embolism in a psychiatric patient.
Topics: Adult; Aggression; Antipsychotic Agents; Autopsy; Benzodiazepines; Bipolar Disorder; Catatonia; Deat | 2014 |
[The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid].
Topics: Adolescent; Anticonvulsants; Child; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Metabol | 2015 |
HDAC5-mTORC1 Interaction in Differential Regulation of Ghrelin and Nucleobindin 2 (NUCB2)/Nesfatin-1.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Animals; Calcium-Binding Proteins; Cell Line; DNA | 2015 |
A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.
Topics: Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Body Mass Index; Case-Control Studies; Dyslip | 2017 |
Does ghrelin really increase in epileptic children treated with valproate?
Topics: Anticonvulsants; Child; Clinical Laboratory Techniques; Epilepsy; Ghrelin; Humans; Molecular Weight; | 2008 |
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Topics: Adiponectin; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Comorb | 2009 |
Nonalcoholic fatty liver disease during valproate therapy.
Topics: Anticonvulsants; Body Mass Index; Child; Epilepsy; Fatty Liver; Fatty Liver, Alcoholic; Female; Huma | 2009 |
High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan.
Topics: Adult; Analysis of Variance; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Blood Glucose | 2009 |
The metabolic syndrome in overweight epileptic patients treated with valproic acid.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Cardiovascular Diseases; Child; Comorbidity; Dyslipide | 2010 |
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod | 2010 |
Metabolic alterations during valproic acid treatment: a prospective study.
Topics: Adolescent; Androgens; Anticonvulsants; Blood Glucose; Body Mass Index; Child; Child, Preschool; Cho | 2009 |
The role of valproate in metabolic disturbances in bipolar disorder patients.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Blood Glucose; Body Mass Index; Cholesterol, HDL; Choleste | 2010 |
Weight gain and insulin resistance in children treated with valproate: the influence of time.
Topics: Anticonvulsants; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Homeostas | 2010 |
Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Female; Humans; Immunoassay; Leptin; Male; Obesity; Pregnanolone; | 2011 |
Fasting insulin and HOMA-index changes in patients treated with valproic acid.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Carbamazepine; Cholesterol, HDL; Epilepsy; Female; | 2011 |
Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Epilepsy; Female; Humans; Male; Metabolic Syndrome | 2012 |
Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Insulin Resistance; Obesity; Polycy | 2002 |
Can diabetes mellitus be induced by medication?
Topics: Adolescent; Antipsychotic Agents; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Male | 2002 |
Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Endocrine System; Epilepsy; Fema | 2003 |
Valproic acid-associated weight gain in older children and teens with epilepsy.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Child; Epilepsy; Female; Follow-Up Studies; Humans; Ma | 2003 |
Do epileptic children treated with valproate have a risk of excessive weight gain?
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Male; Obesi | 2003 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi | 2003 |
Serum insulin and leptin levels and valproate-associated obesity.
Topics: Adult; Anticonvulsants; Body Composition; Body Mass Index; Child; Epilepsy; Feedback; Female; Humans | 2003 |
Long-term reproductive endocrine health in young women with epilepsy during puberty.
Topics: Adolescent; Anticonvulsants; Child; Cohort Studies; Comorbidity; Epilepsy; Female; Finland; Follow-U | 2004 |
Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Dehydroepiandrosterone; Epilepsy; Female; Growth; | 2004 |
Weight change in monozygotic twins treated with valproate.
Topics: Adolescent; Adult; Anticonvulsants; Child, Preschool; Diseases in Twins; Epilepsy; Female; Humans; M | 2005 |
Drug-induced weight gain.
Topics: Anticonvulsants; Antipsychotic Agents; Humans; Obesity; Psychotropic Drugs; Risperidone; Valproic Ac | 2005 |
Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Anticonvulsants; Appetite Regulation; Body Weight; B | 2005 |
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
Topics: Adult; Anticonvulsants; Blood Glucose; C-Peptide; Epilepsy; Fasting; Female; Humans; Hyperinsulinism | 2006 |
Endocrine effects of valproate in adolescent girls with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Body Height; Body Mass Index; Child; Comorbidity; Epilepsy; Fema | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug A | 2008 |
Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Carbamazepine; Comorbidity; Epil | 2007 |
Increased oxidative stress in epileptic children treated with valproic acid.
Topics: Anthropometry; Anticonvulsants; Antioxidants; Blood Chemical Analysis; Blood Glucose; Child; Epileps | 2008 |
Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity.
Topics: Adult; Body Mass Index; Epilepsy; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Mod | 1993 |
Obesity and endocrine disorders in women taking valproate for epilepsy.
Topics: Adult; Body Weight; Carbamazepine; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endocrine | 1996 |
Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Half-Life; Humans; Metabolic Clearance Rate | 1996 |
More on valproate and polycystic ovaries.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Obesity; Polycystic Ovary Syndrome; Va | 1999 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Tolerability of oral loading of divalproex sodium in child psychiatry inpatients.
Topics: Antimanic Agents; Body Weight; Child; Child, Preschool; Humans; Inpatients; Male; Obesity; Retrospec | 2001 |
Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy.
Topics: Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Comorbidity; Dehydroepiandrosterone; Epileps | 2001 |
Altered ovarian function and cardiovascular risk factors in valproate-treated women.
Topics: Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Case-Control S | 2001 |
Serum insulin and leptin levels in valproate-associated obesity.
Topics: Adult; Body Mass Index; Body Weight; Epilepsy; Female; Humans; Insulin; Insulin Resistance; Leptin; | 2002 |
Valproate and palmitate binding to human serum albumin: an hypothesis on obesity.
Topics: Humans; Kinetics; Mathematics; Models, Biological; Obesity; Palmitic Acid; Palmitic Acids; Protein B | 1990 |
Evidence that a GABAergic mechanism influences the development of obesity in obese Zucker rats.
Topics: Animals; beta-Endorphin; Body Weight; gamma-Aminobutyric Acid; Insulin; Obesity; Rats; Rats, Zucker; | 1988 |